52-week Open Label Safety-Tolerability Study

Recruiting now · Phase 3

Conditions studied: Schizophrenia

In brief

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Key facts

Study ID
NCT07369154
Run by
LB Pharmaceuticals Inc.
People needed
900
Starts
2026-04-23
Expected to finish
2029-04-01
Last updated by the study team
2026-07-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.